StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) PT Lowered to $294 at Baird
July 29, 2024 6:56 AM
Baird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $294.00 (from $316.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen
July 29, 2024 6:16 AM
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
July 26, 2024 7:47 AM
Biogen (BIIB): EMA has adopted a negative opinion on MAA of Lecanemab for early Alzheimer’s disease
July 26, 2024 7:22 AM
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024 7:20 AM
